Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. PRYMY
3. SPY
4. SKA-B
5. PBA
6. ALAR
7. CCH:LN
8. META
9. CCHGY
10. PRY:IM

Go back to Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

Myriad Genetics (MYGN) Reports In-Line Q3 EPS

November 2, 2021 8:32 AM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $167.3 million versus the consensus estimate of $165.04 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

... More